How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Do you agree with the proposal not to update section 1.9 bisphosphonate therapy, the use of adjuvant bisphosphonates in people with early or locally advanced breast cancer in the guideline on early and locally advanced breast cancer?Please could let us know if you agree or disagree (yes/no) and provide your comments regarding the reason for your response

  • Question on Consultation

    Do you think that recommendations on adjuvant bisphosphonate therapy need information about assessment of vitamin D levels before starting bisphosphonates, and on the use of calcium and/or vitamin D supplements during treatment, in addition to what the BNF has already covered?Please could let us know if you agree or disagree (yes/no) and provide your comments regarding this

  • Question on Consultation

    Do you think that recommendations 1.9.1 and 1.9.2 need further clarification about approaches to adjuvant bisphosphonate therapy in patients who go through an early menopause due to chemotherapy?Please could let us know if you agree or disagree (yes/no) and provide your comments regarding this

  • Question on Consultation

    Do you have any comments on equality issues?
The content on this page is not current guidance and is only for the purposes of the consultation process.

2022 exceptional surveillance of early and locally advanced breast cancer: diagnosis and management (NICE guideline NG101)

Closed for comments This consultation ended on at   Request commenting lead permission

Surveillance proposal

We will not update section 1.9 bisphosphonate therapy, the use of adjuvant bisphosphonates in people with early or locally advanced breast cancer in the guideline on early and locally advanced breast cancer.

Reason for the exceptional review

The purpose of this exceptional review was to examine any impact on NICE's guideline on early and locally advanced breast cancer of published evidence on the indications for using adjuvant bisphosphonates in people with early or locally advanced breast cancer.

Methods

The exceptional surveillance process consisted of:

  • Considering the evidence used to develop the guideline in 2018.

  • Considering the new evidence that triggered the exceptional review.

  • A focused literature search to identify relevant evidence on adjuvant bisphosphonate therapy in people with early or locally advanced breast cancer.

  • Examining related NICE guidance.

  • Examining the NICE event tracker for relevant ongoing and published events (none identified as relevant on 29th April 2022).

  • Feedback from topic experts.

  • Assessing the new evidence and topic expert feedback against current recommendations to determine whether or not to update the section on adjuvant bisphosphonate therapy in NICE guideline NG101.

  • Consulting on the proposal with stakeholders.

  • Considering comments received during consultation and making any necessary changes to the proposal.

For further details about the process and the possible update decisions that are available, see ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual.